April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Drugs That Prevent Retinal Light Damage Impact CEP Biomarker Levels
K. Renganathan; J. Gu; R. Collier; C. Romano; R. G. Salomon; M. Rayborn; J. G. Hollyfield; J. W. Crabb
Author Affiliations & Notes
  • K. Renganathan
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado
  • J. Gu
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    Department of Chemistry, Case Western Reserve University, Cleveland, Ohio
  • R. Collier
    Retina Research, Alcon, Inc., Fort Worth, Texas
  • C. Romano
    Retina Research, Alcon, Inc., Fort Worth, Texas
  • R. G. Salomon
    Department of Chemistry, Case Western Reserve University, Cleveland, Ohio
  • M. Rayborn
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • J. G. Hollyfield
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • J. W. Crabb
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
    Department of Chemistry, Case Western Reserve University, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  K. Renganathan, Alcon Research LTD., R; J. Gu, None; R. Collier, Alcon Inc., E; C. Romano, Alcon Inc., E; R.G. Salomon, Franz Biomarkers, F; M. Rayborn, None; J.G. Hollyfield, None; J.W. Crabb, Franz Biomarkers; Alcon Research LTD., F.
  • Footnotes
    Support  NIH EY014239, EY014240, EY015638, GM21249, Ohio BRTT 05-29, FFB Center Grant to Cole Eye Institute, RPB Challenge Grant to Cole Eye Institute, RPB Sr Investigator Award (JWC), Steinbach Award (JWC)
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 681. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Drugs That Prevent Retinal Light Damage Impact CEP Biomarker Levels
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      K. Renganathan, J. Gu, R. Collier, C. Romano, R. G. Salomon, M. Rayborn, J. G. Hollyfield, J. W. Crabb; Drugs That Prevent Retinal Light Damage Impact CEP Biomarker Levels. Invest. Ophthalmol. Vis. Sci. 2009;50(13):681.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To determine whether carboxyethylpyrrole (CEP) biomarker concentrations change in rats treated with drugs that prevent light-induced retinopathy. CEP adducts are oxidative protein modifications derived from docosahexaenoate-containing lipids and that increase in rodent retina upon intense light exposure. CEP adducts are elevated in human age-related macular degeneration (AMD) Bruch’s membrane and mean CEP adduct and autoantibody levels are elevated in AMD plasma. AL-8309A is a serotonin 5-HT1A agonist that prevents retinal light damage in rats.

Methods: : Albino rats were dark adapted prior to blue light exposure (3.1 X 103 mW/cm2, =465 nm) for 6 h. Control rats were maintained in normal cyclic light. Rats were injected subcutaneously 3x with 10 mg/kg AL-8309A (2 days, 1 day and 0 hours) before light exposure. Animals were sacrificed immediately following light exposure and retinas and plasma were collected, protected with antioxidants and frozen at -80ºC until analysis. Western analysis with densitometry and ELISA were used to quantify CEP biomarkers in rat retinal homogenates and plasma, respectively. CEP adducts were localized in rat ocular tissues by immunocytochemistry.

Results: : Western analysis showed that CEP adducts are elevated in rat retina and plasma following in vivo blue light exposure and that pretreatment with AL-8309A reduced CEP immunoreactivity ~40% in retina (n > 70 rats) and ~30% in plasma (n = 22 rats). Pretreatment with AL-8309A also reduced CEP autoantibody levels over 30% relative to vehicle + light treated animals (n = 22 rats). Immunocytochemical analyses were consistent with greater CEP immunoreactivity in retina after light exposure and less after drug + light treatment.

Conclusions: : This study supports CEP adducts and autoantibodies as potential biomarkers for monitoring the efficacy of therapeutic agents that impact cellular defense against oxidative stress.

Keywords: radiation damage: light/UV • neuroprotection • oxidation/oxidative or free radical damage 
© 2009, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept